By Candice Choi

Don’t even think of putting the mask away anytime soon.

Despite the expected arrival of COVID-19 vaccines in just a few weeks, it could take several months — probably well into 2021 — before things get back to something close to normal in the U.S. and Americans can once again go to the movies, cheer at an NBA game or give Grandma a hug.

The first, limited shipments of the vaccine would mark just the beginning of what could be a long and messy road toward the end of the pandemic that has upended life and killed more than a quarter-million people in the U.S. In the meantime, Americans are being warned not to let their guard down.

“If you’re fighting a battle and the cavalry is on the way, you don’t stop shooting; you keep going until the cavalry gets here, and then you might even want to continue fighting,” Dr. Anthony Fauci, the nation's top infectious-disease expert, said last week.

This week, AstraZeneca became the third vaccine maker to say early data indicates its shots are highly effective. Pfizer last week asked the U.S. Food and Drug Administration for emergency authorization to begin distributing its vaccine, and Moderna is expected to do the same any day. Federal officials say the first doses will ship within a day of authorization.

But most people will probably have to wait months for shots to become widely available. The Pfizer and Moderna vaccines also each require two doses, meaning people will have to go back for a second shot after three and four weeks, respectively, to get the full protection.

Moncef Slaoui, head of the U.S. vaccine development effort, said on CNN on Sunday that early data on the Pfizer and Moderna shots suggest about 70% of the population would need to be vaccinated to achieve herd immunity — a milestone he said is likely to happen in May.

But along the way, experts say the logistical challenges of the biggest vaccination campaign in U.S. history and public fear and misinformation could hinder the effort and kick the end of the pandemic further down the road.

“It’s going to be a slow process and it’s going to be a process with ups and downs, like we’ve seen already,” said Dr. Bill Moss, an infectious-disease expert at Johns Hopkins University.

SHOTS IN ARMS

Once federal officials give a vaccine the go-ahead, doses that are already being stockpiled will be deployed with the goal of “putting needles in people’s arms” within 24 to 48 hours, said Paul Mango, a U.S. Department of Health and Human Services official involved in the Operation Warp Speed effort to develop COVID-19 vaccines.

Those first shipments are expected to be limited and will be directed to high-risk groups at designated locations, such as front-line health care workers at hospitals.

Federal and state officials are still figuring out exactly how to prioritize those most at risk, including the elderly, prison inmates and homeless people. By the end of January, HHS officials say, all senior citizens should be able to get shots, assuming a vaccine becomes available by the end of 2020.

For everyone else, they expect widespread availability of vaccines would start a couple of months later.

To make shots easily accessible, state and federal officials are enlisting a vast network of providers, such as pharmacies and doctor’s offices.

But some worry long lines won’t be the problem.

“One of the things that may be a factor that hasn’t been discussed that much is: ‘How many will be willing to be vaccinated?’” said Christine Finley, director of Vermont's immunization program. She noted the accelerated development of the vaccine and the politics around it have fueled worries about safety.

Even if the first vaccines prove as effective as suggested by early data, they won’t have much impact if enough people don’t take them.

NO MAGIC BULLET

Vaccines aren’t always effective in everyone: Over the past decade, for example, seasonal flu vaccines have been effective in about 20% to 60% of people who get them.

AstraZeneca, Pfizer, and Moderna say early trial data suggests their vaccine candidates are about 90% or more effective. But those rates could change by the time the studies end.

Also, the definition of “effective” can vary.

Rather than prevent infection entirely, the first COVID-19 vaccines might only prevent illness. Vaccinated people might still be able to transmit the virus, another reason experts say masks will remain crucial for some time.

Another important aspect of vaccines: They can take a while to work.

The first shot of a COVID-19 vaccine might bring about a degree of protection within a couple of weeks, meaning people who get infected might not get as sick as they otherwise would. But full protection could take up to two weeks after the second shot -- or about six weeks after the first shot, said Deborah Fuller, a vaccine expert at the University of Washington.

People who don’t understand that lag could mistakenly think the vaccine made them sick if they happen to come down with COVID-19 soon after a shot. People might also blame the vaccine for unrelated health problems and amplify those fears online.

“All you need is a few people getting on social media,” said Moss of Johns Hopkins University.

There's also the possibility of real side effects. COVID-19 vaccine trials have to include at least 30,000 people, but the chances of a rare side effect turning up are more likely as growing numbers of people are vaccinated.

Even if a link between the vaccine and a possible side effect seems likely, the distribution of shots might not be halted if the risk is deemed small and is outweighed by the benefits, said Dr. Wilbur Chen, a vaccine expert at the University of Maryland.

But Chen said public health officials will need to clearly explain the relative risks to avoid public panic.

Depending on whether the virus mutates in coming years and how long the vaccine’s protection lasts, booster shots, later on, may also be necessary, said Dr. Edward Belongia, a vaccine researcher with the Marshfield Clinic Research Institute in Wisconsin.

Belongia and many others say the coronavirus won’t ever be stamped out and will become one of the many seasonal viruses that sicken people. How quickly will vaccines help reduce the threat of the virus to that level?

“At this point, we just need to wait and see,” Belongia said.

——

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
How to Talk to Your Kids About School Shootings
After the latest school shooting in Uvalde, Texas, it wouldn't be a surprise if the traumatic event takes a toll on your mental health — or that of your children. Amy Morin, the editor-in-chief of Verywell Mind and licensed psychotherapist, joined Cheddar News to share coping skills and offer advice about how to talk to your children about these increasingly common tragic events. “I think its important for parents to know what the school’s plan is, what the teacher's plan is, and then we can have our own plans with kids too," she noted. "It's so important for us to talk to kids about how they're feeling — guaranteed they've heard something about it, so ask them what they know already, use age-appropriate language, and rather than just dismissing their fears by saying don't worry about it or I'm sure you'll be safe, talk to them about their feelings."
Poll Finds Racial Splits on Worries Over COVID-19 Pandemic
An recently conducted AP-NORC poll found that majorities of the Black and Hispanic populations in the U.S. still find themselves either somewhat worried or extremely worried over the pandemic, while more than half of white Americans responded with either being not too worried or not worried at all. Dr. Chris Pernell, the chief strategic integration and health equity officer at University Hospital, joined Cheddar News to talk about how perceptions of COVID-19 differ between groups of Americans. "We’re still seeing people get infected, and because of the toll of the disproportionate impact, we have concerns among the Black and brown community about whether or not they have an increased risk of exposure because of where they work, because of the use of public transportation, because they live in homes that they may not be able to safely quarantine and or isolate in, and because they have at baseline chronic health conditions that may make coronavirus more severe in those persons," she said.
Calif. Probes ExxonMobil Over Accusations of Lying About Plastic Recycling
Judith Enck, a former regional administrator for the EPA and the president of Beyond Plastics, joined Cheddar News to talk about the role of plastics in the climate crisis and California's investigation of ExxonMobil and other oil companies for misleading the public on the ability to recycle plastics. "The reason why petrochemical companies like Exxon have gotten away with selling more and more plastic is that they've lied to the public and told us don't worry about all those negative upstream impacts and downstream impacts of plastics. Just be sure to recycle it. Well, guess what? Plastics largely are not recycled," Enck said.
Need2Know: Ukraine Aid Package, GDP Shrinks & Beijing Lockdown
Catching you up on what you need to know on April 29, 2022, with President Biden asking Congress for a $33 billion aid package for Ukraine, a shrinking GDP potentially leading to a recession, Beijing banning weddings and funerals while closings schools amid COVID, and more.
CVS Health Backs Virtual Care and Digital Medicine Provider Biofourmis in $300 Million Funding Round
Virtual care and digital medicine provider Biofourmis recently raised $300 million in a Series D round led by General Atlantic and with participation from CVS Health. Biofourmis offers at-home care and digital therapies backed by artificial intelligence, which can remotely monitor patients while they are at home. The company says it hopes its technology can improve patient outcomes while reducing the cost and burden of care. Kuldeep Signh Rajput, Founder and CEO of Biofourmis, joins Cheddar News' Closing Bell to discuss.
Moderna Looks for FDA Authorization for COVID Vaccine for Youngest Kids
Moderna is asking the FDA to consider emergency use authorization for its COVID vaccine to be used with children under 6 years old. Dr. Christina Johns, a senior medical advisor at PM Pediatrics, joined Cheddar News to talk about the pharmaceutical company's research into the safety and efficacy of the vaccine for the very youngest of children. "This is very exciting news because children met that goal in their neutralizing antibody response in this age group — means that we really can extrapolate a lot from what we know about data in adults," she said. "I will say that there's a caveat that we have not seen yet the full dataset released, so I'm waiting for that and my fingers are crossed for next week."
Mental Health Platform Real Announces Funding Round of $37 Million, Newly Appointed Adviser Megan Rapinoe
Mental health platform Real recently raised $37 million in a Series B round led by Owl Ventures. Through its mobile app, Real says it provides mental health care at a lower cost than traditional therapy and aims to make mental wellness a part of everyone's daily routine. The company also announced that U.S. soccer star Megan Rapinoe will serve as an adviser to the company. Ariela Safira, Founder & CEO of Real, joins Cheddar News' Closing Bell to discuss.
Need2Know: Musk Mocks Twitter Employee, George Floyd Probe & Drought
Catching you up on what you need to know on April 28, 2022, with Elon Musk mocking Twitter's top legal exec Vijaya Gadde on the platform itself, a probe in George Floyd's death finding discrimination within the Minneapolis police force, the latest California drought leading to new water restrictions, and more.
Load More